CORAL GABLES, Fla., April 28, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that a poster presentation of the visual field safety results obtained from its previously completed, double-blind, placebo-controlled trial in cocaine dependent subjects (CPP-01004) will be made on May 5, 2011 at the leading global ophthalmology research meeting, The Association for Research in Vision and Ophthalmology (ARVO) 2011 Conference, an in-depth, five day forum to be held May 1-5, 2011 at the Broward County/Greater Fort Lauderdale Convention Center in Fort Lauderdale, Florida. The ARVO Conference focuses on advances in ophthalmology research and their potential future applications.
The poster, entitled "Peripheral Visual Field (PVF) Monitoring During Short Term Vigabatrin Treatment in Cocaine Abusers," was authored by Tamara L. Berezina, Albert S. Khouri and Robert D. Fechtner of the Ophthalmology Department of UMDNJ-New Jersey Medical School, and M. Douglas Winship of Catalyst Pharmaceutical Partners, Inc. The poster can be viewed between 8:30 and 10:15 AM ET at Poster Session 523 – "Binocular Vision and Stereopsis, Development, Fields, Fixation and Adaptation." Further, the Company reported that the poster will be added on May 5, 2011 to the Company's website, , under "Events and Presentations."
About Catalyst Pharmaceutical Partners, Inc.
Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting addiction and diseases of the central nervous system. Catalyst has two products in development, and is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109 (vigabatrin), for the treatment of cocaine addiction. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions. Catalyst is also developing CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including drug addiction, epilepsy and for use in the reduction or elimination of addictive liability in the treatment of pain. CPP-115 has been granted orphan-drug designation for the treatment of infantile spasms by the FDA. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase. For more information about Catalyst, go to .
CONTACT: Patrick J. McEnany, Catalyst Pharmaceutical Chief Executive Officer (305) 529-2522 email@example.com Melody Carey, Rx Communications Group Co-President (917) 322-2571 firstname.lastname@example.org